Glaucoma is a group of eye diseases — most often caused by elevated eye pressure — that gradually damage the optic nerve and cause irreversible vision loss, typically starting at the periphery. It is the leading cause of irreversible blindness worldwide, and most vision lost cannot be recovered.
What's actually going on in research
Minimally invasive glaucoma surgeries (MIGS) are being compared with traditional trabeculectomy and with medical therapy in trials to find the best approach for mild and moderate disease. Novel drug delivery systems — including extended-release implants and contact lenses that continuously release pressure-lowering medication — are in development to improve adherence. Neuroprotective drugs targeting the optic nerve directly — rather than just lowering eye pressure — are being tested for the first time.
MIGS procedures
Minimally invasive glaucoma surgeries using tiny stents, drainage channels, and laser approaches are being compared in trials to determine which produces the most sustained pressure reduction with the fewest risks.
Drug delivery implants
Sustained-release bimatoprost implants injected into the eye and glaucoma medication-releasing contact lenses are being tested to eliminate the adherence problem with daily eye drop regimens.
Optic nerve neuroprotection
Drugs like brimonidine and novel agents targeting BDNF signaling aim to protect optic nerve fibers from dying even after eye pressure is controlled — addressing the 30% of patients who progress despite good pressure control.
What to know before you search
Eligibility depends on glaucoma type (open-angle, angle-closure, normal tension), intraocular pressure, visual field loss severity, prior surgery, and current medication use.
What types of trials are currently open
- Surgical trials — Comparing MIGS, traditional trabeculectomy, tube shunt procedures, and laser treatments.
- Drug delivery trials — Testing sustained-release implants, contact lenses, and punctal plugs for continuous medication delivery.
- Neuroprotection trials — Evaluating drugs and devices that protect the optic nerve independent of intraocular pressure.
- Normal tension glaucoma trials — Testing treatments for glaucoma progression despite normal eye pressure.
- Observational studies — Tracking visual field progression rates and biomarkers in treated and untreated glaucoma populations.
Recently added Glaucoma trials
Additive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues
additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated
Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation
This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively. Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.
Find Glaucoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.